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Abstract: Regardless of etiology, peripheral nerve injuries (PNI) result in disruption/loss of neuromuscular
junctions, target muscle denervation, and poor sensorimotor outcomes with associated pain and disability.
Adipose-derived stem cells (ASCs) have shown promise in neuroregeneration. However, there is a paucity
of objective assessments reflective of functional neuroregeneration in experimental PNI. Here, we use a
multimodal, static, and dynamic approach to evaluate functional outcomes after ASC therapy in a rodent
PNI model. Methods Lewis rats were divided into 3 groups: 10 mm sciatic nerve resection (”CUT” group;
n = 10), transection and repair (”REP” group; n = 10), transection and repair plus single-dose ASCs
(”ASC” group; n = 12). Allogeneic (Brown Norway rat) ASCs (1 × 106) were administered intravenously
on postoperative day 1. Functional outcome was assessed by static sciatic index, toe spread factor, and
a dynamic swim test on a weekly basis for 6 weeks. Sciatic nerves and gastrocnemius muscles were
harvested at endpoint (6 weeks) for histological analysis. Results The ASC group showed accelerated
functional recovery on the swim test at 2 weeks postoperatively, with continued improvement over 4
weeks, culminating in superior overall outcomes at 6 weeks compared with the REP group. The CUT
group showed no significant improvement from baseline. Nerve histomorphometry correlated well with
the swim test results in the ASC group. Gastrocnemius muscle weights showed no difference between the
REP and the ASC groups. Conclusion Our study confirms that early, single dose, systemic administration
of ASC after PNI accelerates and enhances overall motor recovery on static and dynamic functional tests
as evidenced by improvements in voluntary as well as involuntary motions.
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INTRODUCTION
Peripheral nerve injury (PNI) has an incidence of 3%–
5% in the United States.1,2 PNI results from trauma, com-
pression (tunnel syndromes), or iatrogenic causes.2,3 The 
resultant motor or sensory loss of function, and unman-
ageable neuropathic pain, can all result in significant 
treatment costs and limited quality of life. Treatment 
approaches remained relatively unchanged throughout 
the past 50 years.4
Even with best surgical apposition, approximately 
only 10% of axons reach the target organs after nerve 
transection.5,6 The speed and quality of overall axonal 
regeneration is critical for neurofunctional outcomes, as 
prolonged denervation of the target muscles leads to a 
poor outcome—for example, loss of motor endplates and 
muscular atrophy.
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Background: Regardless of etiology, peripheral nerve injuries (PNI) result in dis-
ruption/loss of neuromuscular junctions, target muscle denervation, and poor 
sensorimotor outcomes with associated pain and disability. Adipose-derived stem 
cells (ASCs) have shown promise in neuroregeneration. However, there is a pau-
city of objective assessments reflective of functional neuroregeneration in experi-
mental PNI. Here, we use a multimodal, static, and dynamic approach to evaluate 
functional outcomes after ASC therapy in a rodent PNI model.
Methods: Lewis rats were divided into 3 groups: 10 mm sciatic nerve resection 
(“CUT” group; n = 10), transection and repair (“REP” group; n = 10), transec-
tion and repair plus single-dose ASCs (“ASC” group; n = 12). Allogeneic (Brown 
Norway rat) ASCs (1 × 106) were administered intravenously on postoperative day 
1. Functional outcome was assessed by static sciatic index, toe spread factor, and a 
dynamic swim test on a weekly basis for 6 weeks. Sciatic nerves and gastrocnemius 
muscles were harvested at endpoint (6 weeks) for histological analysis.
Results: The ASC group showed accelerated functional recovery on the swim test 
at 2 weeks postoperatively, with continued improvement over 4 weeks, culminating 
in superior overall outcomes at 6 weeks compared with the REP group. The CUT 
group showed no significant improvement from baseline. Nerve histomorphom-
etry correlated well with the swim test results in the ASC group. Gastrocnemius 
muscle weights showed no difference between the REP and the ASC groups.
Conclusion: Our study confirms that early, single dose, systemic administration 
of ASC after PNI accelerates and enhances overall motor recovery on static and 
dynamic functional tests as evidenced by improvements in voluntary as well as 
involuntary motions. (Plast Reconstr Surg Glob Open 2020;8:e2953; doi: 10.1097/
GOX.0000000000002953; Published online 21 July 2020.)
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Treatment paradigms in experimental PNI models 
ranged from neurotrophic agents (drugs/biologics/
growth factors) to cell therapies such as Schwann cells 
or bone marrow or adipose-derived mesenchymal stem 
cells (ASCs).7–13 Characteristics of ASCs such as ease of 
procurement, negligible donor site morbidity, and higher 
yields than other sources of mesenchymal stem cells 
(MSCs) make them ideally suited for local or systemic 
neurotherapies.8,14–19
An ideal functional test to investigate true efficacy 
of neurotherapies must be easy to perform, repeatable 
and reproducible, and objective with low biases and con-
founders. Traditional qualitative/functional assessment 
in experimental PNI such as gait analysis [walking track, 
CatWalk (CatWalk XT 10, Noldus Information Technology, 
Wageningen, The Netherlands), treadmills] only measure 
voluntary activity that depends on subject motivation. 
Alternative assessments such as the swim test, which use 
swimming as a natural, involuntary behavior and elimi-
nate confounders of traditional gait analyses, could be 
better reflective of qualitative functional neuro-behavioral 
outcomes after PNI. Swim test has not been tested in PNI 
and may complement gold-standard quantitative metrics 
of regeneration such as histomorphometry.20,21 Here we 
present the first attempt to evaluate a single dose, systemi-
cally administered, ASC-based neurotherapy protocol in a 
rodent sciatic nerve cut/repair model to facilitate axonal 
regeneration and improve the functional outcomes in PNI.
MATERIALS AND METHODS
This study was conducted in compliance with the University 
of Pittsburgh Institutional Animal Care and Use Committee 
(IACUC) and Association for Assessment and Accreditation 
of Laboratory Animal Care (AALAC) guidelines.
ASC Isolation, Cultivation, and Characterization
ASCs isolated from adipose tissues excised from ingui-
nal fat pads and bilateral epididymes of rats were digested 
with collagenase type II (Worthington Biochemical Corp, 
Lakewood, N.J.) and bovine serum albumin (Millipore, 
Billerica, Mass.) in Hanks’ balanced solution (Cellgro 
Mediatech Inc., Manassas, Va.) for 60 minutes at 37°C while 
shaking. After washing and treatment with erythrocyte lysis 
buffer, the cells were filtered through a sterile gauze. The 
pellet was transferred to culture flasks with Dulbecco’s 
modified Eagle’s medium (Cellgro Mediatech) plus supple-
mental Ham’s F-12 medium (Gibco, Grand Island, N.Y.). 
After 6 hours, nonadherent cells were washed out, retain-
ing only adherent ASCs. Cells were cultured in Dulbecco’s 
modified Eagle’s medium/F12 with 10% fetal bovine serum 
(ATLAS Biologicals, Fort Collins, Colo.), 0.1 μM dexameth-
asone (Sigma-Aldrich, St. Louis, Mo.), 1% penicillin-strep-
tomycin.22 ASC surface marker phenotype was negative for 
CD45 and positive for CD29, CD73 and CD90 as found by 
flow cytometry (FACS Aria, Becton Dickinson).23
Animals and Experimental Protocol
Male Lewis rats (6–8 weeks, 250–300 g; Harlan Labs, 
Indianapolis, Ind.) were randomly assigned to 3 groups: 
(1) 10 mm sciatic nerve resection without repair (“CUT” 
group; n = 10); (2) sciatic nerve transection and repair 
(“REP” group; n = 10); (3) sciatic nerve transection and 
repair with single-dose systemic ASC therapy (“ASC” group; 
n = 12). Buprenorphine was administered (0.05 mg/kg, 
3–4 times per day) for analgesia.
Static sciatic index (SSI) and toe spread factor (TSF) 
were used for static (unenforced) functional assessment, 
and the swim test was used to assess dynamic (forced) 
function. All animals underwent behavioral conditioning 
for 2–3 weeks before surgery. Training swim sessions were 
conducted with the goal of 3 complete swims per session. 
Following baseline (BL) measurements, testing was con-
tinued until 6 weeks (Fig. 1).
Surgical Procedure
Rats were anesthetized with 2% isoflurane (100% oxy-
gen flow at 1 L/min), (VetEqiup; Pleasanton, Calif.). Legs 
were shaved, prepared, and draped, and the right sciatic 
nerve was exposed via dorsolateral incision between 
biceps femoris and gluteus muscle. In the CUT group, 
a 10 mm sciatic nerve segment was resected before its 
bifurcation into peroneal branch to hinder nerve regen-
eration (the segment ending 5 mm proximal to peroneal 
branching). This zone contains motor fibers (for func-
tional return) and also cutaneous afferent fibers that are 
key to pain sensation and proprioception.24 The REP/
ASC groups underwent sciatic nerve transection at same 
level as the CUT group, followed by microsurgical epi-
neural neurorrhaphy with 9-0 nylon sutures at 10 mm 
Fig. 1. Experimental groups and protocol. a, table summarizing the 
experimental groups with surgical interventions and cell therapy. B, 
Experimental protocol showing the interventions and assessments 
on a timeline.
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proximal to branching. The skin was closed with inter-
rupted resorbable sutures.
Static Functional Assessment
The SSI and TSF assess functional motor deficits in 
the peroneal and tibial branches of the sciatic nerve.25 
Animals were placed on a transparent plexiglass walk-
way, ensuring that all 4 limbs uniformly touched the 
surface. High-resolution photographs of paw patterns 
were obtained from below with a camera positioned 
perpendicular to the glass surface at fixed distance and 
zoom. Toe 1–5 (toe spread) and toe 2–4 (intermediate 
toe spread) distances were measured in the operated-on 
(O, right) and naive legs (N, left) to calculate TSF and 
intermediate toe spread factor (ITSF) as follows: TSF 
= (OTSF – NTSF)/NTSF; ITSF = (OITSF – NITSF)/
NITSF. The SSI was calculated as described previously: 
SSI = 108.44(TSF) + 31.85(ITSF) – 5.49.25 (See figure, 
Supplemental Digital Content 1, which displays toe 
spread factor measurement. Representative depiction 
of TSF measurement: the right paw has lost its intrinsic 
ability for toe spread 1 week after sciatic nerve resection. 
In comparison, the uninjured, naive left paw shows nor-
mal toe spread (toe spread, red line) and intermediate 
toe spread (intermediate toe spread, blue line). ****P 
< 0.0001 by 2-way analysis of variance (ANOVA) with 
Tukey’s multiple comparisons, http://links.lww.com/
PRSGO/B422.)
Dynamic Functional Assessment
Animals underwent weekly swim sessions starting 
1 week postoperatively. The setup consisted of a water-
filled plexiglass tank (70 × 25 × 40 cm3; 27°C–30°C) with 
a metallic ladder (Fig. 2A). A high-resolution, cine-cam-
era (GoPro Hero 2; Go Pro Inc., San Mateo, Calif.) was 
placed parallel to long axis of the tank on a tripod at 
100 cm distance with 0-degree vertical and horizontal 
lens tilt at water level. High-frame (120 fps) videos were 
captured, including the middle 50 cm section of the 
tank. Each swim was calculated by 3 consecutive swims 
for a total of 150 cm. Swims were considered valid if the 
animal swam without hesitation from the yellow starting 
line to the exit grid. Recordings were analyzed offline 
for number of strokes observed in the injured hindlimb 
per swim, working angle covered during each stroke, and 
time per swim. Working angle was measured using a free 
shareware (Onde Rulers v1.12.1, Mac Update, Mich.) 
superimposing a goniometer directly onto the video 
at the selected still frame (Fig.  2B). The exact range 
of motion (ie, working angle) was calculated based on 
the angulation between the horizontal water line and 
the degree of motion of mid-foot from the anterior to 
posterior position during each stroke. A performance 
score (PS) was calculated by dividing strokes per run by 
time for the run: PS = (strokes per run)/(time per run) 
× 1000. All image and video measurements were per-
formed by one researcher (P.M.F.) blinded to the groups.
Gastrocnemius Muscle Ratio
The gastrocnemius muscles were harvested bilaterally 
at endpoint, and the ratio of muscle weight on the side 
that was operated on versus the contralateral (naive) side 
determined the degree of muscle atrophy.
Immunohistochemistry and Histomorphometry
Nerve samples 10 mm distal to the coaptation site 
were fixed in Bouin’s solution and processed as described 
earlier.26 After blocking with normal serum, 10-µm-thick 
sections were incubated with the first antibody (neuro-
filament medium chain; 1:400; ThermoScientific/Pierce, 
Waltham, Mass.) and counterstained with Hoechst 33258 
(nucleus) and FluoroMyelin (Sigma-Aldrich). Whole 
nerve cross-sections were imaged with a Nikon 90i micro-
scope (40×). Fiber density (fibers/mm2), total number 
of fibers per distal area of nerve, myelin area, axon area, 
and G-ratio (axon diameter/nerve diameter) were cal-
culated in photomicrographs using MetaMorph software 
(Molecular Devices LLC, San Jose, Calif.). Six random 
regions of interest of myelinated nerve fibers (covering 
80%–90% of the nerve cross-section) were blindly ana-
lyzed in each nerve section.
Statistical Analysis
Prism 8.0 (GraphPad Software, La Jolla, Calif.) was 
used for statistical analysis. Data are presented as mean 
± SD unless otherwise indicated. Differences between the 
groups were assessed by 2-way ANOVA (SSI, TSF, Swim 
Test) with Tukey’s multiple comparisons between groups 
and timepoints. Gastrocnemius ratios were compared with 
1-way ANOVA and Bonferroni’s multiple comparison post-
test. Kruskal–Wallis Test with Dunn’s multiple comparison 
posttest was used for histomorphometry data. A value of 
P < 0.05 was chosen to represent statistical significance.
RESULTS
All animals that were operated on reached the end-
point with no complications such as wound breakdown 
or infections and demonstrated proper weight gain over 
the 6 weeks. (See figure, Supplemental Digital Content 2, 
which displays rat weights. Rats were weighed regu-
larly over the time frame of the experiment, here BL, 4 
weeks, and 6 weeks values are provided for the different 
groups. Not significant difference was noticed between 
the groups, http://links.lww.com/PRSGO/B423.) The 
animals receiving cell injections had no adverse events in 
terms of embolic complications or sudden death.
Static Functional Assessment
A significant drop in both SSI and TSF was observed 
at week 1 compared with that at BL (Fig. 3). SSI for the 
CUT, REP, and ASC groups at week 1 was −105.92 ± 4.02, 
−108.76 ± 7.34, and −104.47 ± 8.54 versus preoperative 
−2.91±7.04 (all groups P < 0.001). The CUT group had 
no improvement the following 6 weeks (−103.37 ± 6.94), 
while the REP and ASC groups revealed progressive 
improvement, culminating in −71.91 ± 16.76 and −46.03 
± 13.66 at week 6 (P < 0.0001 REP versus ASC; P < 0.0001 
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Fig. 2. Swim test setup and measurement. a, a tank measuring 70 × 40 × 25 cm3 (length × height × 
width) with a metallic grid at one end for entry/exit by animals was used for the dynamic (forced func-
tion) tests. the tank was filled with warm tap water (27°C–30°C) to a depth of 30 cm for each swim 
run. the tank was cleaned and water regularly changed after each run. the swims were recorded at 30 
frames/s by a Gopro HErO 7 camera in front of the tank at a defined distance to record the central 50 cm 
length of the swim. B, the recorded videos were analyzed offline, and the working angles of the right 
paw during swim test were measured on single frames (as illustrated). the working angle was measured 
by drawing a line over the mid foot and one on the water surface (for both the most anterior and the 
most posterior part of the cycle, calculating the Δ).
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versus CUT). The ASC group had significantly higher SSI 
recovery compared with the REP group from week 3 to 
endpoint (P < 0.0001 at 6 weeks). Similarly, TSF for the 
CUT, REP, and ASC groups were −0.74 ± 0.02, −0.75 ± 0.05 
and −0.72 ± 0.06 compared with BL CUT group values 
of 0.02 ± 0.05 at week 1. At endpoint, ASC showed the 
best improvement (−0.29 ± 0.10 versus −0.50 ± 0.11 for 
the ASC group and −71 ± 0.05 for the CUT group; P < 
0.0001 for all groups).
Dynamic Functional Assessment
All groups showed a clear drop in overall forced func-
tion on the swim test (stroke number, working angle, and 
PS; Fig. 4) compared with preoperative values [BL, 17.46 
± 2.70 versus 10.83 ± 0.98 (CUT), 10.17 ± 0.40 (REP), and 
12.00 ± 0.93 (ASC) at week 1 (P < 0.001); P > 0.05 between 
groups at week 1; all groups P < 0.0001 versus BL; Fig. 4]. 
ASC showed early improvement in stroke number versus 
REP at week 2 (14.37 ± 1.68 versus 11.83 ± 0.40; P < 0.01), 
but values at endpoint were comparable [15.5 ± 1.05 
(REP) versus 15.71 ± 1.8 (ASC); P > 0.05]. Stroke number 
remained poor in CUT versus REP/ASC groups (11.17 ± 
0.75 at week 6, P < 0.0001 versus REP/ASC).
Overall swim duration was prolonged in all experimen-
tal groups with no intergroup difference (CUT group, 
4695 ± 288; REP group, 4784 ± 221; ASC group, 5273 ± 555 
versus BL, 3295 ± 491 ms; P > 0.05). However, recovery in 
the REP and ASC groups was significantly superior to that 
in the CUT group (REP, 4256 ± 364 and ASC, 3428 ± 332 
versus CUT, 5383 ± 546) over the following 6 weeks, with 
most discernible improvements after week 3 (P < 0.01 REP 
versus ASC; ASC P < 0.0001 week 1 versus week 6).
Working angles dropped to 35.33 ± 7.34 degrees (CUT), 
46.58 ± 8.01 degrees (REP), and 49.56 ± 3.14 degrees 
(ASC) at week 1 versus that at BL (100.78 ± 4.61 degrees, 
P < 0.0001 BL versus week 1; P > 0.05 all groups at week 
1). The REP and ASC groups showed slight improvement 
over 6 weeks, reaching significance (P < 0.0001) in ASC 
at week 6 compared with week 1, while the CUT group 
remained at values similar to that at week 1 (CUT, 33.75 
± 7.21 degrees; REP, 49.25 ± 9.33 degrees; ASC, 49.25 ± 
9.33 degrees at week 6; P < 0.001 between groups).
Overall PS also showed an initial drop compared to 
that at BL (5.40 ± 0.67), but from 2 to 6 weeks, scores in 
the REP and ASC groups were significantly higher than 
that at the CUT group (ASC > REP at endpoint). Scores 
for the CUT, REP, and ASC groups were 2.31 ± 0.23, 2.14 
± 0.16, and 2.29 ± 0.25 at week 1 and 2.13 ± 0.40 (CUT), 
3.64 ± 0.16 (REP), 4.61 ± 0.65 (ASC) at week 6 (REP P > 
0.05 and ASC P < 0.001 versus week 1; P < 0.001 REP versus 
ASC; P < 0.0001 ASC versus CUT).
Gastrocnemius Muscle Ratio
Gastrocnemius muscle ratios at endpoint were signifi-
cantly higher in the REP and ASC group compared with 
the CUT group (REP, 0.43 ± 0.05; ASC, 0.41 ± 0.09; CUT, 
0.24 ± 0.02; P < 0.001; Fig. 5). There was no significant dif-
ference between REP and ASC at endpoint.
Histomorphometry
Distal to site of injury/coaptation, nerve fiber density, 
axon area, and myelin area showed significantly higher 
mean values in ASC compared with the REP group at 
week 6, with no significant trend observed in total fiber 
number (Fig.  6). The G-ratio as marker for nerve matu-
rity revealed no difference between the ASC and the 
REP groups [0.668 ± 0.040 (REP), 0.672 ± 0.036 (ASC) 
and 0.745 ± 0.032 (naive); P > 0.05 ASC versus REP]. 
Nerve fiber density was 10,303 ± 4038 for REP, 14,042 ± 
4325 for ASC, and 12,627 ± 1808 fibers/mm2 for naive 
(P < 0.0001 REP versus ASC), and total fiber numbers were 
2666 ± 1555 (REP), 6486 ± 471.6 (ASC), and 4911 ± 2919 
(naive) (P > 0.05 REP versus ASC). Axon and myelin cross-
section areas were 3.68 ± 2.20 (REP), 4.99 ± 2.92 (ASC), and 
12.50 ± 6.66 µm2 (naive) (P < 0.001 REP versus ASC) and 
13.80 ± 5.88 (REP), 19.41 ± 6.54 (ASC), and 52.82 ± 21.63 
µm2 (naive) (P < 0.0001 REP versus ASC), respectively.
Fig. 3. Static functional tests. Both SSi (a) and tSF (B) tests were per-
formed before the dynamic swim testing for evaluating unenforced 
function. the SSi adequately reflected surgical nerve injury 1 week 
postoperatively in all groups. Both the rEp and aSC groups showed 
a significant improvement in SSi at week 6 compared with the CUt 
group, which did not show significant improvement. a similar result 
was obtained for tSF. aSC, transection and repair with aSC therapy; 
CUt, resection with no repair; rEp, transection and repair. 
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DISCUSSION
Since recognition of the therapeutic potential of 
MSCs, and in particular ASCs,19,27–29 numerous studies 
have investigated their putative positive effects in spinal 
cord injury and PNI.30–32 While the current body of knowl-
edge supports both trans-differentiation to Schwann cell33 
or paracrine effects via neurotropic and neurotrophic 
factors34–36 as possible mechanisms, a combination of 
both might hold true.37,38 Most studies performed have 
explored efficacy of ASCs administered locally,15 seeded in 
conduits,8,14,17,39,40 or deposited in gels,41 rather than incor-
porating ASC-derived neurospheres, exosomes, or condi-
tioned media.15,42
Prior studies have shown positive effects of systemic 
MSCs or ASCs in modulating tissue inflammation and 
nerve injury.43–45 Given the high probability of lung entrap-
ment, we believe the positive functional effects in the cur-
rent study were secondary to paracrine effects, as in earlier 
studies in other models.46,47 Paracrine effects of ASC in 
PNI could involve neurotropic and neurotrophic factors 
acting directly on the regenerating nerve and being per-
missive for a regenerative milieu, favoring SCs action.34–36 
Indeed, neurotrophic factors such as brain-derived neu-
rotrophic factor, nerve growth factor, and glial-derived 
Fig. 4. Dynamic swim test. Four parameters were analyzed offline from the recorded swim tests: strokes 
per swim (a), time to complete the swim run (ms; B), working angle (degree; C), and performance score 
(D). Functional deficits secondary to the intervention were detectable as early as week 1. animals in the 
CUt group took significantly longer time to perform the swim runs than those in the rEp/aSC group at 
6 weeks. Working angle was significantly higher in the aSC group compared with those in the rEp and 
CUt groups at 6 weeks. the aSC group demonstrated a higher overall number of strokes at 1–2 weeks 
compared with the rEp group, suggesting an accelerated functional recovery by aSCs. the rEp group 
showed similar results as the aSC group at 6 weeks. the performance score was significantly higher 
in the aSC group compared with the rEp and CUt groups at 6 weeks. **P < 0.01, ***P < 0.001, ****P < 
0.0001 by 2-way anOVa with tukey’s multiple comparisons.
Fig. 5. Gastrocnemius muscle ratio. Gastrocnemius muscles from the 
operated and the naive side were recovered and weighed at study end 
point, and a ratio of the wet muscle weights on the operated versus 
naive limbs was calculated. Gastrocnemius ratios were significantly 
higher in the rEp/aSC group compared with the CUt group. no dif-
ference was noted between the repaired groups at endpoint. ***P < 
0.001 by 1-way anOVa and Bonferroni’s multiple comparison posttest.
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neurotrophic factor secreted or upregulated by ASCs aug-
ment axonal regrowth and myelination.36,48,49
The resection group had a significantly lower gastroc-
nemius ratio, indicating muscle atrophy as seen by oth-
ers.50 However, significantly higher values in the treated 
groups point to the benefit of ASC and simple repair in 
preventing atrophy.15,51 The SSI scores with early single-
dose ASC treatment were superior to the results from 
crush studies with late administration (after 6 weeks), 
alluding to an immunomodulatory effect of ASC during 
early phases of neuroinflammation following PNI.15 Such 
positive effects were confirmed on nerve histomorphom-
etry, especially nerve fiber density, axon, and myelin area 
in the ASC-treated group.
Despite their value in reflecting the extent and qual-
ity of nerve regeneration, nerve histomorphometry, 
Fig. 6. Histomorphometric nerve analysis. nerve samples were procured at endpoint and for analysis of 
multiple morphologic parameters: fiber density (a), number of fibers per cross-section (B), axon area (C), 
myelin area (D), and G-ratio (E, axon diameter/nerve diameter). the aSC group exhibited significantly 
higher values for all the parameters except for G-ratio. Values in the contralateral naive sciatic nerve 
were used for baseline reference comparison. ***P < 0.001, **** P < 0.0001 by Kruskal-Wallis test with 
Dunn’s multiple comparison posttest. F, representative cross section of the sciatic nerve as measured by 
metamorph Software (molecular Devices llC, San Jose, Calif.) to assess nerve fiber density and myelin-
ization (red, myelin; green, axon).
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gastrocnemius weigh ratios, and electrophysiology suf-
fer from poor correlation or lack functional/behavioral 
information.14,15 Indeed, lack of tests combining objective 
functional motor evaluation with ease of repetitive testing 
without need for expensive setups is one of the chief limi-
tations in nerve regeneration research.
Reports of systemic use of ASCs in PNI are scarce and, 
to best of our knowledge, is limited to a single study of a 
mouse model of sciatic nerve crush injury, which demon-
strated improved function on SSI with ASC therapy 1 week 
after crush injury and improvement in histomorphometric 
outcomes.45 No dynamic functional testing was performed.
Although static functional measures such as walking 
track analysis or treadmills are decades old,25,52 modifica-
tions like the Catwalk XT system have gained popularity 
in experimental models of PNI53,54 or neuropathic pain 
in rodents.55–57 Although these studies claim that CatWalk 
can purportedly quantify mechanical allodynia as well 
as assess subtle alterations across multiple parameters, 
other studies emphasize its unreliability in PNI.58,59 One 
limitation of CatWalk is the need for voluntary locomo-
tion for evaluation of gait parameters. Persistent pain 
and gravity can limit load bearing. A recent test that 
has shown promise in overcoming these limitations is 
the dynamic swim test. This is a measure of global limb 
functional activity and involuntary motor activity in the 
absence of gravity. Although the swim test has been 
used in models of depression or central nervous system 
injury,20,21 it has never been evaluated in PNI. We com-
pared functional assessment of animals with resected 
versus repaired sciatic nerves with CatWalk and swim test 
and found that both were sensitive enough to detect loss 
of function after injury, but the CatWalk system was not 
able to distinguish between “repair” and “no repair” and 
monitor functional recovery in the early phase of PNI. 
(See figure, Supplemental Digital Content 3, which dis-
plays functional analysis using the CatWalk system. After 
sciatic nerve resection (10 mm; CUT) and sciatic cut 
and repair (REP), different parameters were recorded 
over 6 weeks, including BL (preoperative) assessment 
(X axis). The parameters are divided into static (A) and 
dynamic (B). The injured side (RH) is compared with 
the noninjured side (LH) and a ratio is calculated. #P < 
0.05 vs BL. The CatWalk system is a computed video gait 
analysis system for quantifying functional recovery. Rats 
cross a 1.5-m-long and a 10-cm-narrow tunnel with a glass 
surface and black walls to enter a goal box at the oppo-
site end of the tunnel, and a camera records the runs. 
The CatWalk system software provides a wide variety of 
static and dynamic parameters, including the ones we 
selected for being most appropriate to our setting. “Print 
length” is defined as the horizontal length of the com-
plete print, and the “print area” is defined as the surface 
area of the complete print. The CatWalk software creates 
a rectangular box around each paw print, allowing for 
measurement of the length and area. “Maximum inten-
sity” reflects the maximum pressure exerted by a single 
paw and is expressed in arbitrary units. CatWalk further 
offers parameters that incorporate time measurements 
for dynamic assessment of functional recovery. The 
“swing phase” is determined as the duration in which a 
paw has no detectable contact with the walkway. Contrary 
to the swing phase, the “stand phase” describes the time 
of detectable paw contact with the glass plate. A complete 
step cycle consists of a stand and swing phase. “Single 
stance” describes the duration of ground contact in sec-
onds for a single paw where the contralateral side does 
not touch the ground. The “duty cycle” is calculated as: 
duty cycle = stand/(stand + swing) × 100%, http://links.
lww.com/PRSGO/B424.)
In our study, infusion of ASCs 1 day after PNI demon-
strated beneficial effects in both static and dynamic testing. 
Early improvement in terms of strokes and swim duration 
in the first 2 weeks in the ASC group could be interpreted 
as a result of anti-inflammatory and immunomodulatory 
function with reduction of postoperative pain, swelling, and 
reduction of surgical trauma, since clinically relevant nerve 
regeneration is not expected that early. Our results concur 
with Marconi et al45 in the murine nerve crush model. At 6 
weeks, swim duration and overall performance score were 
significantly improved after ASC therapy, while non ASC-
treated animals exhibited worse functional return.
Our swim test system is easy to set up, using a com-
mercially available camera, the GoPro. It can be expanded 
with additional mirrors, sophisticated lighting, and pro-
fessional recording devices for 3D assessment of complex 
functional parameters.20 The buoyancy, absence of gravity, 
and lack of ground reaction forces acting on the animal’s 
injured leg allow for functional testing with less pain and 
decreased need of strength, allowing an early detection of 
functional recovery with less biases.
Study limitations
First, analysis of gastrocnemius weights and histo-
morphometry occurred only at endpoint, preventing 
an understanding of the dynamics of early regenera-
tion. In the functional testing, we could see a differen-
tial response between both repair groups at early time 
points (1–3 weeks), which could be explained mecha-
nistically by examination of tissue samples at these time 
points. Second, the cut/repair model may not be as 
robust as critical gap models for evaluation of neuro-
therapies. Third, evaluation of only a single cell dosage 
and timepoint prevented elucidation of the mechanism 
by which ASC administration promotes nerve regenera-
tion. Although the current study did not monitor homing 
of injected cells, our group previously demonstrated that 
intravenous injected MSCs home to perivascular niches in 
inflamed tissue (eg, in the setting of critical ischemia).46 
Other groups have reported that cells get entrapped in 
the lung capillaries after injection but nevertheless exert 
positive therapeutic effects.60
CONCLUSIONS
In summary, our results suggest that early systemic ASC 
administration is safe and augments nerve regeneration 
after peripheral nerve transection and repair, resulting 
in increased motor function compared with nerve repair 
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without cell therapy. Of note, the SSI outcomes reflected 
specific reinnervation of the intrinsic muscle of the paw, 
while the swim test provided an objective assessment of 
involuntary measures such as hind paw function, tail 
movement, velocity, forelimb strokes, and hind forelimb 
coordination. Both SSI and swim test outcomes were sup-
ported by gastrocnemius muscle scores and histomor-
phometry data.
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